Physician profile
Tran Ha
NPI 1437700663
$11,216.76
in general payments reported to CMS, 2019-2025
60 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,077 · 2022: $3,917 · 2023: $1,564 · 2024: $1,027 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,783 · Travel and Lodging: $873 · Long Term Medical Supply Or Device Loan: $299 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.17 |
| Travel and Lodging | $872.79 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $267.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,440.33 | 2021 | |
| Medtronic, INC. | $1,335.91 | 2025 | Synchromedii |
| Janssen Biotech, INC. | $659.09 | 2021-2024 | Erleada, Akeega, Rybrevant |
| Lilly USA, LLC | $610.98 | 2021-2025 | Retevmo, Verzenio, Amyvid |
| Janssen Scientific Affairs, LLC | $597.17 | 2022 | |
| Incyte Corporation | $477.72 | 2021-2023 | Monjuvi |
| Novartis Pharmaceuticals Corporation | $463.82 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $403.85 | 2021-2023 | Calquence, Tagrisso |
| Celgene Corporation | $377.91 | 2022-2023 | Pomalyst, Opdualag |
| Seagen INC. | $358.92 | 2021-2023 | Padcev, Adcetris |
| Merck Sharp & Dohme LLC | $295.90 | 2021-2023 | Keytruda |
| Amgen INC. | $283.48 | 2021-2023 | Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $265.32 | 2021-2023 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $240.56 | 2021-2024 | Jemperli, Zejula |
| Harmony Biosciences LLC | $170.86 | 2024-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tran Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.